To find the fee schedule for a specific code/service, please use the HCPCS Screen in the Fiscal Intermediary Standard System (FISS). Instructions and field descriptions can be found in Chapter 2, Section 2.6 of the FISS User Manual available in the Claims Center of our website.
Fees for outpatient services not paid under a Prospective Payment System can be found via the Part B Single Code Search Tool located on the Part B Fee Schedule page.
HCPCS Code |
|
Description |
A4563 |
A |
Rectal control system for vaginal insertion, for long term use, includes pump |
A5514 |
A |
For diabetics only, multiple density insert, made by direct carving with cam |
A6460 |
A |
Synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, |
A6461 |
A |
Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but |
A9513 |
A |
Lutetium lu 177, dotatate, therapeutic, 1 millicurie |
A9589 |
A |
Instillation, hexaminolevulinate hydrochloride, 100 mg |
B4105 |
A |
In-line cartridge containing digestive enzyme(s) for enteral feeding, each |
C1823 |
A |
Generator, neurostimulator (implantable), non-rechargeable, with transvenous |
C8937 |
A |
Computer-aided detection, including computer algorithm analysis of breast mri |
C9034 |
A |
Injection, dexamethasone 9%, intraocular, 1 mcg |
C9035 |
A |
Injection, aripiprazole lauroxil (aristada initio), 1 mg |
C9036 |
A |
Injection, patisiran, 0.1 mg |
C9037 |
A |
Injection, risperidone (perseris), 0.5 mg |
C9038 |
A |
Injection, mogamulizumab-kpkc, 1 mg |
C9039 |
A |
Injection, plazomicin, 5 mg |
C9407 |
A |
Iodine i-131 iobenguane, diagnostic, 1 millicurie |
C9408 |
A |
Iodine i-131 iobenguane, therapeutic, 1 millicurie |
C9462 |
A |
Injection, delafloxacin, 1 mg |
C9749 |
A |
Repair of nasal vestibular lateral wall stenosis with implant(s) |
C9751 |
A |
Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by |
C9752 |
A |
Destruction of intraosseous basivertebral nerve, first two vertebral bodies, |
C9753 |
A |
Destruction of intraosseous basivertebral nerve, each additional vertebral |
C9754 |
A |
Creation of arteriovenous fistula, percutaneous; direct, any site, including |
C9755 |
A |
Creation of arteriovenous fistula, percutaneous using magnetic-guided arterial |
D0412 |
A |
Blood glucose level test - in-office using a glucose meter |
D1516 |
A |
Space maintainer - fixed - bilateral, maxillary |
D1517 |
A |
Space maintainer - fixed - bilateral, mandibular |
D1526 |
A |
Space maintainer - removable - bilateral, maxillary |
D1527 |
A |
Space maintainer - removable - bilateral, mandibular |
D5282 |
A |
Removable unilateral partial denture - one piece cast metal (including clasps |
D5283 |
A |
Removable unilateral partial denture - one piece cast metal (including clasps |
D5876 |
A |
Add metal substructure to acrylic full denture (per arch) |
D9130 |
A |
Temporomandibular joint dysfunction - non-invasive physical therapies |
D9613 |
A |
Infiltration of sustained release therapeutic drug - single or multiple sites |
D9944 |
A |
Occlusal guard - hard appliance, full arch |
D9945 |
A |
Occlusal guard - soft appliance, full arch |
D9946 |
A |
Occlusal guard - hard appliance, partial arch |
D9961 |
A |
Duplicate/copy patient's records |
D9990 |
A |
Certified translation or sign-language services - per visit |
E0447 |
A |
Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount |
E0467 |
A |
Home ventilator, multi-function respiratory device, also performs any or all of |
G0068 |
A |
Professional services for the administration of anti-infective, pain |
G0069 |
A |
Professional services for the administration of subcutaneous immunotherapy for |
G0070 |
A |
Professional services for the administration of chemotherapy for each infusion |
G0071 |
A |
Payment for communication technology-based services for 5 minutes or more of a |
G0076 |
A |
Brief (20 minutes) care management home visit for a new patient. for use only |
G0077 |
A |
Limited (30 minutes) care management home visit for a new patient. for use only |
G0078 |
A |
Moderate (45 minutes) care management home visit for a new patient. for use |
G0079 |
A |
Comprehensive (60 minutes) care management home visit for a new patient. for |
G0080 |
A |
Extensive (75 minutes) care management home visit for a new patient. for use |
G0081 |
A |
Brief (20 minutes) care management home visit for an existing patient. for use |
G0082 |
A |
Limited (30 minutes) care management home visit for an existing patient. for |
G0083 |
A |
Moderate (45 minutes) care management home visit for an existing patient. for |
G0084 |
A |
Comprehensive (60 minutes) care management home visit for an existing patient. |
G0085 |
A |
Extensive (75 minutes) care management home visit for an existing patient. for |
G0086 |
A |
Limited (30 minutes) care management home care plan oversight. for use only in |
G0087 |
A |
Comprehensive (60 minutes) care management home care plan oversight. for use |
G2000 |
A |
Blinded administration of convulsive therapy procedure, either |
G2010 |
A |
Remote evaluation of recorded video and/or images submitted by an established |
G2011 |
A |
Alcohol and/or substance (other than tobacco) abuse structured assessment |
G2012 |
A |
Brief communication technology-based service, e.g. virtual check-in, by a |
G9873 |
A |
First medicare diabetes prevention program (mdpp) core session was attended by |
G9874 |
A |
Four total medicare diabetes prevention program (mdpp) core sessions were |
G9875 |
A |
Nine total medicare diabetes prevention program (mdpp) core sessions were |
G9876 |
A |
Two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) |
G9877 |
A |
Two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) |
G9878 |
A |
Two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) |
G9879 |
A |
Two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) |
G9880 |
A |
The mdpp beneficiary achieved at least 5% weight loss (wl) from his/her |
G9881 |
A |
The mdpp beneficiary achieved at least 9% weight loss (wl) from his/her |
G9882 |
A |
Two medicare diabetes prevention program (mdpp) ongoing maintenance sessions |
G9883 |
A |
Two medicare diabetes prevention program (mdpp) ongoing maintenance sessions |
G9884 |
A |
Two medicare diabetes prevention program (mdpp) ongoing maintenance sessions |
G9885 |
A |
Two medicare diabetes prevention program (mdpp) ongoing maintenance sessions |
G9890 |
A |
Bridge payment: a one-time payment for the first medicare diabetes prevention |
G9891 |
A |
Mdpp session reported as a line-item on a claim for a payable mdpp expanded |
G9978 |
A |
Remote in-home visit for the evaluation and management of a new patient for use |
G9979 |
A |
Remote in-home visit for the evaluation and management of a new patient for use |
G9980 |
A |
Remote in-home visit for the evaluation and management of a new patient for use |
G9981 |
A |
Remote in-home visit for the evaluation and management of a new patient for use |
G9982 |
A |
Remote in-home visit for the evaluation and management of a new patient for use |
G9983 |
A |
Remote in-home visit for the evaluation and management of an established |
G9984 |
A |
Remote in-home visit for the evaluation and management of an established |
G9985 |
A |
Remote in-home visit for the evaluation and management of an established |
G9986 |
A |
Remote in-home visit for the evaluation and management of an established |
G9987 |
A |
Bundled payments for care improvement advanced (bpci advanced) model home visit |
J0185 |
A |
Injection, aprepitant, 1 mg |
J0517 |
A |
Injection, benralizumab, 1 mg |
J0567 |
A |
Injection, cerliponase alfa, 1 mg |
J0584 |
A |
Injection, burosumab-twza 1 mg |
J0599 |
A |
Injection, c-1 esterase inhibitor (human), (haegarda), 10 units |
J0841 |
A |
Injection, crotalidae immune f(ab')2 (equine), 120 mg |
J1301 |
A |
Injection, edaravone, 1 mg |
J1454 |
A |
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg |
J1628 |
A |
Injection, guselkumab, 1 mg |
J1746 |
A |
Injection, ibalizumab-uiyk, 10 mg |
J2062 |
A |
Loxapine for inhalation, 1 mg |
J2797 |
A |
Injection, rolapitant, 0.5 mg |
J3245 |
A |
Injection, tildrakizumab, 1 mg |
J3304 |
A |
Injection, triamcinolone acetonide, preservative-free, extended-release, |
J3316 |
A |
Injection, triptorelin, extended-release, 3.75 mg |
J3397 |
A |
Injection, vestronidase alfa-vjbk, 1 mg |
J3398 |
A |
Injection, voretigene neparvovec-rzyl, 1 billion vector genomes |
J3591 |
A |
Unclassified drug or biological used for esrd on dialysis |
J7170 |
A |
Injection, emicizumab-kxwh, 0.5 mg |
J7177 |
A |
Injection, human fibrinogen concentrate (fibryga), 1 mg |
J7203 |
A |
Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, |
J7318 |
A |
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg |
J7329 |
A |
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg |
J9044 |
A |
Injection, bortezomib, not otherwise specified, 0.1 mg |
J9057 |
A |
Injection, copanlisib, 1 mg |
J9153 |
A |
Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine |
J9173 |
A |
Injection, durvalumab, 10 mg |
J9229 |
A |
Injection, inotuzumab ozogamicin, 0.1 mg |
J9311 |
A |
Injection, rituximab 10 mg and hyaluronidase |
J9312 |
A |
Injection, rituximab, 10 mg |
L8608 |
A |
Miscellaneous external component, supply or accessory for use with the argus ii |
L8698 |
A |
Miscellaneous component, supply or accessory for use with total artificial |
L8701 |
A |
Powered upper extremity range of motion assist device, elbow, wrist, hand with |
L8702 |
A |
Powered upper extremity range of motion assist device, elbow, wrist, hand, |
M1000 |
A |
Pain screened as moderate to severe |
M1001 |
A |
Plan of care to address moderate to severe pain documented on or before the |
M1002 |
A |
Plan of care for moderate to severe pain not documented on or before the date |
M1003 |
A |
Tb screening performed and results interpreted within twelve months prior to |
M1004 |
A |
Documentation of medical reason for not screening for tb or interpreting |
M1005 |
A |
Tb screening not performed or results not interpreted, reason not given |
M1006 |
A |
Disease activity not assessed, reason not given |
M1007 |
A |
>=50% of total number of a patient's outpatient ra encounters assessed |
M1008 |
A |
<50% of total number of a patient's outpatient ra encounters assessed |
M1009 |
A |
Patient treatment and final evaluation complete |
M1010 |
A |
Patient treatment and final evaluation complete |
M1011 |
A |
Patient treatment and final evaluation complete |
M1012 |
A |
Patient treatment and final evaluation complete |
M1013 |
A |
Patient treatment and final evaluation complete |
M1014 |
A |
Patient treatment and final evaluation complete |
M1015 |
A |
Patient treatment and final evaluation complete |
M1016 |
A |
Female patients unable to bear children |
M1017 |
A |
Patient admitted to palliative care services |
M1018 |
A |
Patients with an active diagnosis or history of cancer (except basal cell and |
M1019 |
A |
Adolescent patients 12 to 17 years of age with major depression or dysthymia |
M1020 |
A |
Adolescent patients 12 to 17 years of age with major depression or dysthymia |
M1021 |
A |
Patient had only urgent care visits during the performance period |
M1022 |
A |
Patients who were in hospice at any time during the performance period |
M1023 |
A |
Adolescent patients 12 to 17 years of age with major depression or dysthymia |
M1024 |
A |
Adolescent patients 12 to 17 years of age with major depression or dysthymia |
M1025 |
A |
Patients who were in hospice at any time during the performance period |
M1026 |
A |
Patients who were in hospice at any time during the performance period |
M1027 |
A |
Imaging of the head (ct or mri) was obtained |
M1028 |
A |
Documentation of patients with primary headache diagnosis and imaging other |
M1029 |
A |
Imaging of the head (ct or mri) was not obtained, reason not given |
M1030 |
A |
Patients with clinical indications for imaging of the head |
M1031 |
A |
Patients with no clinical indications for imaging of the head |
M1032 |
A |
Adults currently taking pharmacotherapy for oud |
M1033 |
A |
Pharmacotherapy for oud initiated after june 30th of performance period |
M1034 |
A |
Adults who have at least 180 days of continuous pharmacotherapy with a |
M1035 |
A |
Adults who are deliberately phased out of medication assisted treatment (mat) |
M1036 |
A |
Adults who have not had at least 180 days of continuous pharmacotherapy with a |
M1037 |
A |
Patients with a diagnosis of lumbar spine region cancer at the time of the |
M1038 |
A |
Patients with a diagnosis of lumbar spine region fracture at the time of the |
M1039 |
A |
Patients with a diagnosis of lumbar spine region infection at the time of the |
M1040 |
A |
Patients with a diagnosis of lumbar idiopathic or congenital scoliosis |
M1041 |
A |
Patient had cancer, fracture or infection related to the lumbar spine or |
M1042 |
A |
Functional status measurement with score was obtained utilizing the oswestry |
M1043 |
A |
Functional status measurement with score was not obtained utilizing the |
M1044 |
A |
Functional status was measured by the oswestry disability index (odi version |
M1045 |
A |
Functional status measurement with score was obtained utilizing the oxford knee |
M1046 |
A |
Functional status measurement with score was not obtained utilizing the oxford |
M1047 |
A |
Functional status was measured by the oxford knee score (oks) patient reported |
M1048 |
A |
Functional status measurement with score was obtained utilizing the oswestry |
M1049 |
A |
Functional status measurement with score was not obtained utilizing the |
M1050 |
A |
Functional status was measured by the oswestry disability index (odi version |
M1051 |
A |
Patient had cancer, fracture or infection related to the lumbar spine or |
M1052 |
A |
Leg pain was not measured by the visual analog scale (vas) within three months |
M1053 |
A |
Leg pain was measured by the visual analog scale (vas) within three months |
M1054 |
A |
Patient had only urgent care visits during the performance period |
M1055 |
A |
Aspirin or another antiplatelet therapy used |
M1056 |
A |
Prescribed anticoagulant medication during the performance period, history of |
M1057 |
A |
Aspirin or another antiplatelet therapy not used, reason not given |
M1058 |
A |
Patient was a permanent nursing home resident at any time during the |
M1059 |
A |
Patient was in hospice or receiving palliative care at any time during the |
M1060 |
A |
Patient died prior to the end of the performance period |
M1061 |
A |
Patient pregnancy |
M1062 |
A |
Patient immunocompromised |
M1063 |
A |
Patients receiving high doses of immunosuppressive therapy |
M1064 |
A |
Shingrix vaccine documented as administered or previously received |
M1065 |
A |
Shingrix vaccine was not administered for reasons documented by clinician (e.g. |
M1066 |
A |
Shingrix vaccine not documented as administered, reason not given |
M1067 |
A |
Hospice services for patient provided any time during the measurement period |
M1068 |
A |
Adults who are not ambulatory |
M1069 |
A |
Patient screened for future fall risk |
M1070 |
A |
Patient not screened for future fall risk, reason not given |
M1071 |
A |
Patient had any additional spine procedures performed on the same date as the |
Q2042 |
A |
Tisagenlecleucel, up to 600 million car-positive viable t cells, including |
Q4183 |
A |
Surgigraft, per square centimeter |
Q4184 |
A |
Cellesta, per square centimeter |
Q4185 |
A |
Cellesta flowable amnion (25 mg per cc); per 0.5 cc |
Q4186 |
A |
Epifix, per square centimeter |
Q4187 |
A |
Epicord, per square centimeter |
Q4188 |
A |
Amnioarmor, per square centimeter |
Q4189 |
A |
Artacent ac, 1 mg |
Q4190 |
A |
Artacent ac, per square centimeter |
Q4191 |
A |
Restorigin, per square centimeter |
Q4192 |
A |
Restorigin, 1 cc |
Q4193 |
A |
Coll-e-derm, per square centimeter |
Q4194 |
A |
Novachor, per square centimeter |
Q4195 |
A |
Puraply, per square centimeter |
Q4196 |
A |
Puraply am, per square centimeter |
Q4197 |
A |
Puraply xt, per square centimeter |
Q4198 |
A |
Genesis amniotic membrane, per square centimeter |
Q4200 |
A |
Skin te, per square centimeter |
Q4201 |
A |
Matrion, per square centimeter |
Q4202 |
A |
Keroxx (2.5g/cc), 1cc |
Q4203 |
A |
Derma-gide, per square centimeter |
Q4204 |
A |
Xwrap, per square centimeter |
Q5103 |
A |
Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg |
Q5104 |
A |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg |
Q5105 |
A |
Injection, epoetin alfa, biosimilar, (retacrit) (for esrd on dialysis), 100 |
Q5106 |
A |
Injection, epoetin alfa, biosimilar, (retacrit) (for non-esrd use), 1000 units |
Q5107 |
A |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
Q5108 |
A |
Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg |
Q5109 |
A |
Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg |
Q5110 |
A |
Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram |
Q9991 |
A |
Injection, buprenorphine extended-release (sublocade), less than or equal to |
Q9992 |
A |
Injection, buprenorphine extended-release (sublocade), greater than 100 mg |
T4545 |
A |
Incontinence product, disposable, penile wrap, each |
V5171 |
A |
Hearing aid, contralateral routing device, monaural, in the ear (ite) |
V5172 |
A |
Hearing aid, contralateral routing device, monaural, in the canal (itc) |
V5181 |
A |
Hearing aid, contralateral routing device, monaural, behind the ear (bte) |
V5211 |
A |
Hearing aid, contralateral routing system, binaural, ite/ite |
V5212 |
A |
Hearing aid, contralateral routing system, binaural, ite/itc |
V5213 |
A |
Hearing aid, contralateral routing system, binaural, ite/bte |
V5214 |
A |
Hearing aid, contralateral routing system, binaural, itc/itc |
V5215 |
A |
Hearing aid, contralateral routing system, binaural, itc/bte |
V5221 |
A |
Hearing aid, contralateral routing system, binaural, bte/bte |
0012M |
A |
Oncology (urothelial), mrna, gene expression profiling by real-time |
0013M |
A |
Oncology (urothelial), mrna, gene expression profiling by real-time |
0035U |
A |
Testing for presence of prion protein in cerebrospinal fluid |
0036U |
A |
Exome gene analysis for somatic mutation in tumor tissue |
0037U |
A |
DNA gene analysis of 324 genes in solid organ tumor tissue |
0038U |
A |
Measurement of vitamin D in serum |
0039U |
A |
Testing for anti-DNA antibody |
0040U |
A |
Gene analysis (t(9;22)) for translocation analysis |
0041U |
A |
IgM antibody detection test for Borrelia burgdorferi |
0042U |
A |
IgG antibody detection test for Borrelia burgdorferi |
0043U |
A |
IgM antibody detection test for Tick-Borne Relapsing Fever Borrelia group |
0044U |
A |
IgM antibody detection test for Tick-Borne Relapsing Fever Borrelia group |
0045U |
A |
mRNA gene analysis of 12 genes in breast ductal carcinoma in situ tumor tissue |
0046U |
A |
Gene analysis (fms-related tyrosine kinase 3) for internal tandem duplication |
0047U |
A |
mRNA gene analysis of 17 genes in prostate tumor tissue |
0048U |
A |
DNA gene analysis of 468 genes in solid organ tumor tissue |
0049U |
A |
Gene analysis (nucleophosmin) |
0050U |
A |
DNA gene analysis of targeted sequences in 194 genes for acute myelogenous |
0051U |
A |
Testing for presence of 31 prescription drugs in urine |
0052U |
A |
Measurement of all five major lipoprotein classes and subclasses in blood |
0053U |
A |
FISH analysis of 4 genes in prostate needle biopsy specimen |
0054U |
A |
Measurement of 14 or more drug classes in capillary blood |
0055U |
A |
DNA gene analysis of 96 target sequences in plasma for heart transplant |
0056U |
A |
Whole genome sequencing in blood or bone marrow for acute myelogenous leukemia |
0057U |
A |
mRNA gene analysis of 51 genes in solid organ tumor tissue |
0058U |
A |
Measurement of antibodies to Merkel cell polyoma virus oncoprotein in serum |
0059U |
A |
Test for presence of antibodies to Merkel cell polyoma virus oncoprotein in |
0060U |
A |
Gene analysis for identical twins in maternal blood |
0061U |
A |
Spatial frequency domain imaging of skin |
0062U |
A |
Autoimmune (systemic lupus erythematosus), igg and igm analysis of 80 |
0063U |
A |
Neurology (autism), 32 amines by lc-ms/ms, using plasma, algorithm reported as |
0064U |
A |
Antibody, treponema pallidum, total and rapid plasma reagin (rpr), immunoassay, |
0065U |
A |
Syphilis test, non-treponemal antibody, immunoassay, qualitative (rpr) |
0066U |
A |
Placental alpha-micro globulin-1 (pamg-1), immunoassay with direct optical |
0067U |
A |
Oncology (breast), immunohistochemistry, protein expression profiling of 4 |
0068U |
A |
Candida species panel (c. albicans, c. glabrata, c. parapsilosis, c. kruseii, c |
0069U |
A |
Oncology (colorectal), microrna, rt-pcr expression profiling of mir-31-3p, |
0070U |
A |
Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug |
0071U |
A |
Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug |
0072U |
A |
Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug |
0073U |
A |
Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug |
0074U |
A |
Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug |
0075U |
A |
Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug |
0076U |
A |
Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug |
0077U |
A |
Immunoglobulin paraprotein (m-protein), qualitative, immunoprecipitation and |
0078U |
A |
Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, |
0079U |
A |
Comparative dna analysis using multiple selected single-nucleotide |
10004 |
A |
Fine needle aspiration of additional lesion |
10005 |
A |
Fine needle aspiration of first lesion using ultrasound guidance |
10006 |
A |
Fine needle aspiration of additional lesion using ultrasound guidance |
10007 |
A |
Fine needle aspiration of first lesion using fluoroscopice guidance |
10008 |
A |
Fine needle aspiration of additional lesion using fluoroscopice guidance |
10009 |
A |
Fine needle aspiration of first lesion using CT guidance |
10010 |
A |
Fine needle aspiration of additional lesion using CT guidance |
10011 |
A |
Fine needle aspiration of first lesion using MR guidance |
10012 |
A |
Fine needle aspiration of additional lesion using MR guidance |
11102 |
A |
Tangential biopsy of single skin lesion |
11103 |
A |
Tangential biopsy of additional skin lesion |
11104 |
A |
Punch biopsy of single skin lesion |
11105 |
A |
Punch biopsy of additional skin lesion |
11106 |
A |
Incisional biopsy of single skin lesion |
11107 |
A |
Incisional biopsy of additional skin lesion |
20932 |
A |
Donor bone and joint graft to joint surface and neighboring bone |
20933 |
A |
Half-cylindrical donor bone graft |
20934 |
A |
Cylindrical donor bone graft |
27369 |
A |
Injection of contrast for imaging of knee joint |
33274 |
A |
Insertion or replacement of permanent leadless pacemaker into lower right |
33275 |
A |
Removal of permanent leadless pacemaker into lower right chamber of heart via |
33285 |
A |
Insertion of heart rhythm monitor under skin |
33286 |
A |
Removal of heart rhythm monitor from under skin |
33289 |
A |
Insertion of wireless pressure sensor into lung artery via catheter |
33440 |
A |
Replacement of aortic valve by translocation of pulmonary valve, replacement of |
33866 |
A |
Graft to half of aortic artery arch |
36572 |
A |
Insertion of central venous catheter for infusion using imaging guidance, |
36573 |
A |
Insertion of central venous catheter for infusion using imaging guidance, |
38531 |
A |
Open biopsy or excision of lymph nodes in groin |
43762 |
A |
Replacement of stomach stoma tube accessed through skin |
43763 |
A |
Replacement of stomach stoma tube accessed through skin with revision of stoma |
50436 |
A |
Enlargement of existing opening into urinary tract accessed through skin using |
50437 |
A |
Enlargement of existing opening into urinary tract accessed through skin and |
53854 |
A |
Destruction of prostate tissue accessed through urethra using radiofrequency |
76391 |
A |
Magnetic resonance (eg, vibration) elastography |
76978 |
A |
Ultrasound using targeted microbubble contrast of first lesion |
76979 |
A |
Ultrasound using targeted microbubble contrast of additional lesion |
76981 |
A |
Elastography ultrasound of organ tissue |
76982 |
A |
Elastography ultrasound of first lesion |
76983 |
A |
Elastography ultrasound of additional lesion |
77046 |
A |
MRI of one breast |
77047 |
A |
MRI of both breasts |
77048 |
A |
MRI of one breast with and without contrast |
77049 |
A |
MRI of both breasts with and without contrast |
81163 |
A |
Gene analysis (breast cancer 1 and 2) of full sequence |
81164 |
A |
Gene analysis (breast cancer 1 and 2) for duplication or deletion variants |
81165 |
A |
Gene analysis (breast cancer 1) of full sequence |
81166 |
A |
Gene analysis (breast cancer 1) for duplication or deletion variants |
81167 |
A |
Gene analysis (breast cancer 2) for duplication or deletion variants |
81171 |
A |
Gene analysis (fragile X mental retardation 2) for abnormal alleles |
81172 |
A |
Gene analysis (fragile X mental retardation 2) for characterization of alleles |
81173 |
A |
Gene analysis (androgen receptor) of full sequence |
81174 |
A |
Gene analysis (androgen receptor) for known familial variant |
81177 |
A |
Gene analysis (atropin 1) for abnormal alleles |
81178 |
A |
Gene analysis (ataxin 1) for abnormal alleles |
81179 |
A |
Gene analysis (ataxin 2) for abnormal alleles |
81180 |
A |
Gene analysis (ataxin 3) for abnormal alleles |
81181 |
A |
Gene analysis (ataxin 7) for abnormal alleles |
81182 |
A |
Gene analysis (ataxin 8 opposite strand non-protein codingÙ) for abnormal |
81183 |
A |
Gene analysis (ataxin 10) for abnormal alleles |
81184 |
A |
Gene analysis (calcium voltage-gated channel subunit alpha1 A) for abnormal |
81185 |
A |
Gene analysis (calcium voltage-gated channel subunit alpha1 A) of full sequence |
81186 |
A |
Gene analysis (calcium voltage-gated channel subunit alpha1 A) for known |
81187 |
A |
Gene analysis (CCH-type zinc finger nucleic acid binding protein) for abnormal |
81188 |
A |
Gene analysis (cystatin B) for abnormal alleles |
81189 |
A |
Gene analysis (cystatin B) of full sequence |
81190 |
A |
Gene analysis (cystatin B) for known familial variants |
81204 |
A |
Gene analysis (androgen receptor) for characterization of alleles |
81233 |
A |
Gene analysis (Bruton's tyrosine kinase) for common variants |
81234 |
A |
Gene analysis (DM1 protein kinase) for abnormal alleles |
81236 |
A |
Gene analysis (enhancer of zeste 2 polycomb repressive complex 2 subunit) of |
81237 |
A |
Gene analysis (enhancer of zeste 2 polycomb repressive complex 2 subunit) for |
81239 |
A |
Gene analysis (DM1 protein kinase) for characterization of alleles |
81271 |
A |
Gene analysis (Huntingtin) for abnormal alleles |
81274 |
A |
Gene analysis (Huntingtin) for characterization of alleles |
81284 |
A |
Gene analysis (frataxin) for abnormal alleles |
81285 |
A |
Gene analysis (frataxin) for characterization of alleles |
81286 |
A |
Gene analysis (frataxin) of full sequence |
81289 |
A |
Gene analysis (frataxin) for known familial variants |
81305 |
A |
Gene analysis (myeloid differentiation primary response 88) for p.Leu265Pro |
81306 |
A |
Gene analysis (nudix hydrolase 15) for common variants |
81312 |
A |
Gene analysis (polyAÙ binding protein nuclear 1) for abnormal alleles |
81320 |
A |
Gene analysis (phospholipase C gamma 2) for common variants |
81329 |
A |
Gene analysis (survival of motor neuron 1, telomeric) for dosage/deletion |
81333 |
A |
Gene analysis (transforming growth factor beta-induced) for common variants |
81336 |
A |
Gene analysis (survival of motor neuron 1, telomeric) of full sequence |
81337 |
A |
Gene analysis (survival of motor neuron 1, telomeric) for known familial |
81343 |
A |
Gene analysis (protein phosphatase 2 regulatory subunit Bbeta) for abnormal |
81344 |
A |
Gene analysis (TATA box binding protein) for abnormal alleles |
81345 |
A |
Gene analysis (telomerase reverse transcriptase) targeted sequence analysis |
81443 |
A |
Genomic sequence analysis panel for severe inherited conditions with sequencing |
81518 |
A |
mRNA gene analysis of 11 genes in breast tumor tissue |
81596 |
A |
Biochemical assays for evaluation of chronic Hepatitis C virus infection |
82642 |
A |
Measurement of dihydrotestosterone |
83722 |
A |
Measurement of small dense low density lipoprotein cholesterol |
90689 |
A |
Inactivated quadrivalent influenza vaccine for injection into muscle, 0.25 ml |
92273 |
A |
Full field recording of retinal electrical responses to external stimuli with |
92274 |
A |
Multifocal recording of retinal electrical responses to external stimuli with |
93264 |
A |
Remote monitoring of wireless pressure sensor in lung artery with qualified |
95836 |
A |
Recording of brain cortex electrical responses to implanted stimulation device |
95976 |
A |
Electronic analysis of implanted brain, spinal cord or peripheral stimulation |
95977 |
A |
Electronic analysis of implanted brain, spinal cord or peripheral stimulation |
95983 |
A |
Electronic analysis of implanted brain, spinal cord or peripheral stimulation |
95984 |
A |
Electronic analysis of implanted brain, spinal cord or peripheral stimulation |
96112 |
A |
Developmental test administration by qualified health care professional with |
96113 |
A |
Developmental test administration by qualified health care professional with |
96121 |
A |
Neurobehavioral status examination by qualified health care professional with |
96130 |
A |
Psychological testing evaluation by qualified health care professional, first |
96131 |
A |
Psychological testing evaluation by qualified health care professional, |
96132 |
A |
Neuropsychological testing evaluation by qualified health care professional, |
96133 |
A |
Neuropsychological testing evaluation by qualified health care professional, |
96136 |
A |
Psychological or neuropsychological test administration and scoring by |
96137 |
A |
Psychological or neuropsychological test administration and scoring by |
96138 |
A |
Psychological or neuropsychological test administration and scoring by |
96139 |
A |
Psychological or neuropsychological test administration and scoring by |
96146 |
A |
Psychological or neuropsychological test administration and scoring by single |
97151 |
A |
Behavior identification assessment by qualified health care professional, each |
97152 |
A |
Behavior identification assessment by technician under direction of qualified |
97153 |
A |
Adaptive behavior treatment by protocol, administered by technician under |
97154 |
A |
Adaptive behavior treatment by protocol, administered by technician under |
97155 |
A |
Adaptive behavior treatment with protocol modification administered by |
97156 |
A |
Family adaptive behavior treatment guidance by qualified health care |
97157 |
A |
Family adaptive behavior treatment guidance by qualified health care |
97158 |
A |
Group adaptive behavior treatment with protocol modification administered by |
99451 |
A |
Telephone or internet assessment and management service provided by |
99452 |
A |
Telephone or internet referral service, 30 minutes |
99453 |
A |
Remote monitoring of physiologic parameters, initial set-up and patient |
99454 |
A |
Remote monitoring of physiologic parameters, initial supply of devices with |
99457 |
A |
Remote monitoring of physiologic parameters management services, 20 minutes or |
99491 |
A |
Chronic care management services by qualified health care professional, 30 |
0505T |
A |
Reopening of arteries in thigh and behind knee with placement of stent via |
0506T |
A |
Measurement of pigment density in retinas with interpretation and report |
0507T |
A |
Near infrared dual imaging of tear glands with interpretation and report |
0508T |
A |
Ultrasound measurement of bone density in shin bone |
0509T |
A |
Pattern recording of retinal electrical responses to external stimuli with |
0510T |
A |
Removal of implant from tunnel on outer side of foot (sinus tarsi) |
0511T |
A |
Removal and reinsertion of implant from tunnel on outer side of foot (sinus |
0512T |
A |
High energy shock wave therapy for initial wound of outer body surface |
0513T |
A |
High energy shock wave therapy for additional wound of outer body surface |
0514T |
A |
Visual axis identification using patient fixation during operation |
0515T |
A |
Insertion of complete wireless heart stimulator system for pacing of lower left |
0516T |
A |
Insertion of electrode of wireless heart stimulator system for pacing of lower |
0517T |
A |
Insertion of pulse generator components of wireless heart stimulator system for |
0518T |
A |
Removal of pulse generator components of wireless heart stimulator system for |
0519T |
A |
Removal and replacement of pulse generator components of wireless heart |
0520T |
A |
Removal and replacement of pulse generator components of wireless heart |
0521T |
A |
Evaluation of parameters of wireless heart stimulator system for pacing of |
0522T |
A |
Evaluation, testing, and programming adjustment of wireless heart stimulator |
0523T |
A |
Measurement fractional flow reserve in arteries of heart with 3D functional |
0524T |
A |
Chemical destruction of insufficient vein of arm or leg via catheter using |
0525T |
A |
Insertion or replacement of complete monitoring system for deficient blood flow |
0526T |
A |
Insertion or replacement of electrode of monitoring system for deficient blood |
0527T |
A |
Insertion or replacement of implantable monitor of monitoring system for |
0528T |
A |
Evaluation, testing, and programming adjustment of monitoring system for |
0529T |
A |
Evaluation of parameters of monitoring system for deficient blood flow in heart |
0530T |
A |
Removal of complete monitoring system for deficient blood flow in heart muscle |
0531T |
A |
Removal of electrode of monitoring system for deficient blood flow in heart |
0532T |
A |
Removal of implantable monitor of monitoring system for deficient blood flow in |
0533T |
A |
Continuous recording of movement disorder symptoms for 8-10 days with set-up, |
0534T |
A |
Continuous recording of movement disorder symptoms for 8-10 days with set-up, |
0535T |
A |
Continuous recording of movement disorder symptoms for 8-10 days with data |
0536T |
A |
Continuous recording of movement disorder symptoms for 8-10 days with download |
0537T |
A |
Harvesting of blood-derived T white blood cells (T lymphocytes) for chimeric |
0538T |
A |
Preparation of blood-derived T white blood cells (T lymphocytes) for |
0539T |
A |
Receipt and preparation of blood-derived T white blood cells (T lymphocytes) |
0540T |
A |
Administration of blood-derived T white blood cells (T lymphocytes) for |
0541T |
A |
Imaging of heart muscle using magnetocardiography to detect deficient blood |
0542T |
A |
Interpretation and report of imaging of heart muscle using magnetocardiography |